Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK2637 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK2637 120 mg |
| 2 | EXPERIMENTAL | MK2637 50 mg |
| 3 | PLACEBO_COMPARATOR | Placebo |
| 4 | ACTIVE_COMPARATOR | Dextromethorphan 220 mg |
| 5 | ACTIVE_COMPARATOR | Dextromethorphan 110 mg |
| Name | Type | Description |
|---|---|---|
| MK2637 | DRUG | Single dose of 120 mg MK2637 capsules in one of five treatment periods. |
| Comparator: MK2637 | DRUG | Single dose of 50 mg MK2637 capsules in one of five treatment periods. |
| Comparator: Placebo | DRUG | Single dose of placebo only in one of five treatment periods. |
| Comparator: Dextromethorphan | DRUG | Single dose of 220 mg dextromethorphan capsules in one of five treatment periods. |
Inclusion Criteria: * Subject is right-handed * Subject is in good health * Subject is a nonsmoker Exclusion Criteria: * Subject works a night shift * Subject has a history of any illness that might make participation in the study unsafe or confound the study results * Subject has a history of he...
MK2637 is an investigational small molecule being studied for the treatment of schizophrenia. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its effects on cerebral cortex excitability in the context of schizophrenia research.
MK2637 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research on this investigational compound for schizophrenia.
MK2637 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The compound is still in early-stage clinical testing for schizophrenia.
MK2637 has one completed Phase 1 clinical trial registered as NCT00934466. This study, titled "Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)," enrolled 15 male participants aged 18 years and older. The trial was randomized, double-blind, and placebo-controlled.
No, MK2637 is not the same as dextromethorphan. The clinical trial NCT00934466 studied the effects of single doses of both MK2637 and dextromethorphan on cerebral cortex excitability, indicating they are separate compounds being evaluated in the same study.